Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

ABSTRACT:

Introduction

The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China. The guidelines for hepatitis C recommend the use of gene-specific regimens when the regional 3b prevalence rate greater than 5%. This study is to explore rationality of this proportion and the cost-effectiveness to implement pan-genotypic regimens in China.

Methods

A decision Markov model was developed from the health system perspective to evaluate the effectiveness and cost-effectiveness between pan-genotypic and gene-specific treatment regimens for hepatitis C patients. Additionally, we set a regional genotype 3b patient proportion of 0-100% to explore at which proportion it is necessary to perform

SUBMITTER: Tu Y 

PROVIDER: S-EPMC10848349 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature